Längle-Rouault F, Patzel V, Benavente A, Taillez M, Silvestre N, Bompard A, Sczakiel G, Jacobs E, Rittner K
Transgène S.A., 67000 Strasbourg, France.
J Virol. 1998 Jul;72(7):6181-5. doi: 10.1128/JVI.72.7.6181-6185.1998.
A 100-fold increase in luciferase activity was observed in 293 cells, stably expressing Epstein-Barr nuclear antigen 1 (EBNA1; 293-EBNA1 cells), that had been transiently transfected with plasmids carrying Epstein-Barr virus (EBV) oriP sequences. This increase was observed in comparison to reporter gene activity obtained after transfection with a plasmid carrying no oriP sequences. The luciferase gene on these plasmids was under the control of either the cytomegalovirus immediate-early 1 gene enhancer-promoter (CMV IE1) or the Rous sarcoma virus promoter. The increase of reporter gene activity was not due to plasmid replication, since a similar enhancement was observed in the presence of aphidicolin, an inhibitor of replicative DNA synthesis, or after deletion of the dyad symmetry (DS) element within oriP. Luciferase production was not increased in the presence of only the DS element. Microinjection of plasmids carrying the CMV IE1 promoter-driven luciferase gene with or without oriP sequences into the nuclei of 293-EBNA1 cells resulted in a 17-fold increase in luciferase activity. Cytoplasmic injection of these plasmids led to an enhancement of luciferase activity of up to 100-fold. This difference in the factor of activation after nuclear or cytoplasmic injection could be ascribed to increased transport of plasmids carrying oriP from the cytoplasm to the nucleus in the presence of EBNA1. These data suggest the possibility of substantially increasing the apparent expression of a gene under the control of a strong constitutive promoter in the presence of oriP sequences and EBNA1. This improvement in expression is due to intranuclear enhancement of gene expression. oriP-specific transport of plasmid DNA from the cytoplasm of 293-EBNA1 cells to the nucleus seems to contribute to the observed effect.
在稳定表达爱泼斯坦 - 巴尔核抗原1(EBNA1;293 - EBNA1细胞)的293细胞中,观察到在瞬时转染携带爱泼斯坦 - 巴尔病毒(EBV)oriP序列的质粒后,荧光素酶活性增加了100倍。与转染不携带oriP序列的质粒后获得的报告基因活性相比,观察到了这种增加。这些质粒上的荧光素酶基因受巨细胞病毒立即早期1基因增强子 - 启动子(CMV IE1)或劳斯肉瘤病毒启动子的控制。报告基因活性的增加不是由于质粒复制,因为在存在抑制复制性DNA合成的阿非迪霉素的情况下,或在删除oriP内的二元对称(DS)元件后,观察到了类似的增强。仅存在DS元件时,荧光素酶产量没有增加。将携带CMV IE1启动子驱动的荧光素酶基因且有或没有oriP序列的质粒显微注射到293 - EBNA1细胞的细胞核中,导致荧光素酶活性增加了17倍。将这些质粒进行细胞质注射导致荧光素酶活性增强高达100倍。核注射或细胞质注射后激活因子的这种差异可归因于在EBNA1存在下,携带oriP的质粒从细胞质到细胞核的转运增加。这些数据表明,在存在oriP序列和EBNA1的情况下,有可能大幅增加在强组成型启动子控制下基因的表观表达。这种表达的改善是由于基因表达在核内增强。293 - EBNA1细胞细胞质中质粒DNA的oriP特异性转运似乎促成了观察到的效果。